Variation in Antibiotic Use for Children Hospitalized With Inflammatory Bowel Disease Exacerbation: A Multicenter

Matthew P Kronman1, Jeffrey S Gerber2, Priya A Prasad2

  • 1Division of Infectious Diseases, Seattle Children's Hospital, University of Washington School of Medicine matthew.kronman@seattlechildrens.org.

Insights

Antibiotic use for pediatric inflammatory bowel disease (IBD) hospitalizations varies widely across children's hospitals. This study characterized antibiotic prescribing patterns for pediatric IBD exacerbations.

Area of Science:

  • Pediatric Gastroenterology
  • Infectious Disease Management
  • Healthcare Quality Improvement

Background:

  • Antibiotics are frequently used for pediatric inflammatory bowel disease (IBD) exacerbations, but their utilization patterns in hospitalized children are not well-characterized.
  • Administrative data can be validated to identify hospitalizations for IBD exacerbations, enabling large-scale analysis.

Purpose of the Study:

  • To validate administrative data for identifying pediatric IBD exacerbations.
  • To characterize the patterns and variability of antibiotic use in children hospitalized with IBD exacerbations across US children's hospitals.

Main Methods:

  • Chart review of 409 IBD patients at 3 tertiary care children's hospitals to validate administrative data.
  • Analysis of 5063 hospitalizations for IBD exacerbation at 36 children's hospitals (2007-2009) using a validated case definition.
  • Mixed-effects logistic regression to estimate hospital-specific antibiotic utilization rates, adjusting for patient and hospital factors.

Main Results:

  • Administrative codes for IV steroids or endoscopy showed 79% positive predictive value and 71% sensitivity for IBD exacerbation hospitalizations.
  • Antibiotics were administered during 40.7% of pediatric IBD exacerbations, with significant hospital-level variation (27%-71%).
  • Common antibiotic regimens included metronidazole alone (26.9%), metronidazole with ciprofloxacin (10.3%), and ampicillin/gentamicin/metronidazole (7.0%).

Conclusions:

  • Significant unexplained variability exists in antibiotic prescribing for hospitalized pediatric IBD exacerbations.
  • Disease severity or hospital volume did not explain the observed differences in antibiotic use.
  • Further research is needed to establish optimal antibiotic therapy guidelines for pediatric IBD exacerbations.
Abstract

Related Concept Videos

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy01:30

Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy

Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the colonic...
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Inflammatory Bowel Disease IV: Clinical Manifestations01:20

Inflammatory Bowel Disease IV: Clinical Manifestations

Inflammatory bowel disease (IBD) encompasses two major chronic disorders—ulcerative colitis and Crohn’s disease—each characterized by relapsing episodes of gastrointestinal inflammation. Although they share certain clinical features, their patterns of involvement and manifestations differ in ways that aid diagnosis and guide management.Ulcerative ColitisUlcerative colitis is limited to the colon and rectum and involves continuous inflammation of the mucosal layer. The disease course is marked...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...